Complete financial analysis of Aura Biosciences, Inc. (AURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aura Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Safestore Holdings plc (SAFE.L) Income Statement Analysis – Financial Results
- MOGU Inc. (MOGU) Income Statement Analysis – Financial Results
- DIAGNOS Inc. (ADK.V) Income Statement Analysis – Financial Results
- Rinnai Corporation (RINIF) Income Statement Analysis – Financial Results
- Hana Financial Group Inc. (086790.KS) Income Statement Analysis – Financial Results
Aura Biosciences, Inc. (AURA)
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| Gross Profit | -1.30M | -1.18M | -835.00K | -831.00K | -509.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.23M | 42.24M | 25.16M | 18.04M | 19.62M |
| General & Administrative | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Other Expenses | 0.00 | -5.00K | -11.00K | 3.00K | -44.00K |
| Operating Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Cost & Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Interest Income | 0.00 | 1.86M | 13.00K | 3.00 | 5.00 |
| Interest Expense | 0.00 | 0.00 | 13.00K | 3.00K | 5.00K |
| Depreciation & Amortization | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| EBITDA | -83.70M | -59.12M | -34.42M | -21.38M | -23.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.99M | -60.30M | -35.25M | -22.21M | -24.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.72M | 1.53M | -1.00K | 0.00 | -60.00K |
| Income Before Tax | -76.27M | -58.76M | -35.25M | -22.21M | -24.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 137.00K | -1.53M | -830.00K | 3.00K | 5.00K |
| Net Income | -76.41M | -57.23M | -34.42M | -22.21M | -24.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| EPS Diluted | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| Weighted Avg Shares Out | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
| Weighted Avg Shares Out (Dil) | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of bel-sar...
Why Shares of Aura Biosciences Jumped This Week
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following...
Aura Biosciences Announces Pricing of Public Offering of Common Stock
BOSTON--( BUSINESS WIRE )--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of...
Aura Biosciences Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its common...
Aura Biosciences Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares...
Aura Biosciences Announces Proposed Public Offering of Common Stock
BOSTON--( BUSINESS WIRE )--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock....
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development...
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development...
Source: https://incomestatements.info
Category: Stock Reports